This segment focuses on the research, development, and clinical trials of novel antibiotics to combat bacterial infections, with a primary focus on addressing the growing threat of antibiotic resistance. The core activity involves the development of ibezapolstat, a first-in-class antibiotic targeting the polymerase IIIC enzyme, and ACX-375C, a potential treatment for gram-positive bacteria. Research and development activities include preclinical studies, Phase II and planned Phase III clinical trials, and formulation development. The company utilizes advanced methodologies in drug discovery and development, including identifying and targeting specific bacterial mechanisms. The therapeutic areas addressed include Clostridium difficile infections (CDI) and infections caused by gram-positive bacteria such as MRSA and VRE. The patient impact is significant, as these infections pose serious health risks and can be life-threatening. Market positioning is based on addressing unmet medical needs in antibiotic resistance. Future opportunities include expanding the pipeline with additional antibiotic candidates and seeking regulatory approvals. Regulatory and clinical aspects involve navigating FDA approval processes and conducting clinical trials to demonstrate safety and efficacy. Partnerships and collaborations are pursued to support research and development efforts.